A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer

✍ Scribed by Ratner, E S; Keane, F K; Lindner, R; Tassi, R A; Paranjape, T; Glasgow, M; Nallur, S; Deng, Y; Lu, L; Steele, L; Sand, S; Muller, R-U; Bignotti, E; Bellone, S; Boeke, M; Yao, X; Pecorelli, S; Ravaggi, A; Katsaros, D; Zelterman, D; Cristea, M C; Yu, H; Rutherford, T J; Weitzel, J N; Neuhausen, S L; Schwartz, P E; Slack, F J; Santin, A D; Weidhaas, J B

• Book ID: 118270985
• Publisher: Nature Publishing Group
• Year: 2011
• Tongue: English
• Weight: 758 KB
• Volume: 31
• Category: Article
• ISSN: 0950-9232
• DOI: 10.1038/onc.2011.539